Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hemant Surgical Industries's earnings before interest and taxes (EBIT) for the
six
months ended in Mar. 2026 was ₹183 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹276 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Hemant Surgical Industries's annualizedROC % for the quarter that ended in Mar. 2026 was 16.65%.
Hemant Surgical Industries's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 37.94%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Hemant Surgical Industries's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 4.92%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Hemant Surgical Industries's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hemant Surgical Industries EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Hemant Surgical Industries's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Hemant Surgical Industries's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹276 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hemant Surgical Industries (BOM:543916) has a EBIT of ₹276 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Hemant Surgical Industries.
Is Hemant Surgical Industries' EBIT too high?
Hemant Surgical Industries' current EBIT is ₹276 Mil. Overall, Hemant Surgical Industries has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hemant Surgical Industries' EBIT compare to ABT and SYK?
Hemant Surgical Industries' EBIT of ₹276 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Hemant Surgical Industries. Hemant Surgical Industries's current EBIT is ₹276 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemant Surgical Industries stock overvalued right now?
Based on GuruFocus' analysis, Hemant Surgical Industries (BOM:543916) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹332.62, compared to a current price of ₹380.90 — trading 14.5% above its estimated fair value. The current EBIT is ₹276 Mil. Hemant Surgical Industries' overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Hemant Surgical Industries (BOM:543916), the current EBIT is ₹276 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hemant Surgical Industries (BOM:543916) Overvalued in 2026?
Based on GuruFocus' analysis, Hemant Surgical Industries stock appears to be overvalued.
The current stock price of ₹380.90 is trading 14.5% above its estimated GF Value™ of ₹332.62.
GuruFocus considers Hemant Surgical Industries to be Modestly Overvalued.
Key valuation signals for BOM:543916:
EBIT: ₹276 Mil
GF Value™: ₹332.62 vs. price of ₹380.90 (14.5% above fair value)
No single metric tells the full story. See the BOM:543916 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hemant Surgical Industries Ltd is engaged in Importing, manufacturing, and marketing quality surgical and Pharmaceutical Products at an economical price. Its product offerings cover a wide spectrum of equipment and disposables required for (i) Renal Care, (ii) Cardiovascular Disease, (iii) Respiratory Disease, (iv) Critical Care and Radiology, and (v) Surgical disposables. Its products include JMS Meditape, JMS Infusion Set, JMS Scalp Vein Set, Ventilators, ECG Machines, and others.
80GF Score
Get the complete analysis for BOM:543916
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543916 has been successfully added to your 
